These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 19458008)

  • 41. Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctions.
    Svarovskaia ES; Barr R; Zhang X; Pais GC; Marchand C; Pommier Y; Burke TR; Pathak VK
    J Virol; 2004 Apr; 78(7):3210-22. PubMed ID: 15016842
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In search of authentic inhibitors of HIV-1 integration.
    Debyser Z; Cherepanov P; Van Maele B; De Clercq E; Witvrouw M
    Antivir Chem Chemother; 2002 Jan; 13(1):1-15. PubMed ID: 12180645
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Usefulness of Integrase resistance testing in proviral HIV-1 DNA in patients with Raltegravir prior failure.
    Fernández-Caballero JÁ; Chueca N; Álvarez M; Mérida MD; López J; Sánchez JA; Vinuesa D; Martínez MÁ; Hernández J; García F
    BMC Infect Dis; 2016 May; 16():197. PubMed ID: 27177767
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells.
    Hazuda DJ; Felock P; Witmer M; Wolfe A; Stillmock K; Grobler JA; Espeseth A; Gabryelski L; Schleif W; Blau C; Miller MD
    Science; 2000 Jan; 287(5453):646-50. PubMed ID: 10649997
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Emerging pharmacology: inhibitors of human immunodeficiency virus integration.
    Hazuda D; Iwamoto M; Wenning L
    Annu Rev Pharmacol Toxicol; 2009; 49():377-94. PubMed ID: 18928385
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Raltegravir: the first HIV integrase inhibitor.
    Cocohoba J; Dong BJ
    Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir.
    Canducci F; Ceresola ER; Saita D; Castagna A; Gianotti N; Underwood M; Burioni R; Lazzarin A; Clementi M
    J Antimicrob Chemother; 2013 Nov; 68(11):2525-32. PubMed ID: 23798668
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance.
    Lataillade M; Chiarella J; Kozal MJ
    Antivir Ther; 2007; 12(4):563-70. PubMed ID: 17668566
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Integrase inhibitors in the treatment of HIV-1 infection.
    Powderly WG
    J Antimicrob Chemother; 2010 Dec; 65(12):2485-8. PubMed ID: 20852268
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Human immunodeficiency virus type 1 (HIV-1) integration: a potential target for microbicides to prevent cell-free or cell-associated HIV-1 infection.
    Terrazas-Aranda K; Van Herrewege Y; Hazuda D; Lewi P; Costi R; Di Santo R; Cara A; Vanham G
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2544-54. PubMed ID: 18474579
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.
    Murray JM; Emery S; Kelleher AD; Law M; Chen J; Hazuda DJ; Nguyen BY; Teppler H; Cooper DA
    AIDS; 2007 Nov; 21(17):2315-21. PubMed ID: 18090280
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways.
    Fransen S; Gupta S; Danovich R; Hazuda D; Miller M; Witmer M; Petropoulos CJ; Huang W
    J Virol; 2009 Nov; 83(22):11440-6. PubMed ID: 19759152
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Integrase inhibitor reversal dynamics indicate unintegrated HIV-1 dna initiate de novo integration.
    Thierry S; Munir S; Thierry E; Subra F; Leh H; Zamborlini A; Saenz D; Levy DN; Lesbats P; Saïb A; Parissi V; Poeschla E; Deprez E; Delelis O
    Retrovirology; 2015 Mar; 12():24. PubMed ID: 25808736
    [TBL] [Abstract][Full Text] [Related]  

  • 54. LEDGIN-mediated Inhibition of Integrase-LEDGF/p75 Interaction Reduces Reactivation of Residual Latent HIV.
    Vranckx LS; Demeulemeester J; Saleh S; Boll A; Vansant G; Schrijvers R; Weydert C; Battivelli E; Verdin E; Cereseto A; Christ F; Gijsbers R; Debyser Z
    EBioMedicine; 2016 Jun; 8():248-264. PubMed ID: 27428435
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Efficacy of raltegravir: from healthy volunteers to phase III trials].
    Gatell JM
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():29-33. PubMed ID: 19572423
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Integrase inhibitors for the treatment of HIV infection.
    Pace P; Rowley M
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):471-9. PubMed ID: 18600564
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Increased number of single-LTR HIV-1 DNA junctions correlates with HIV-1 antigen expression and CD4+ cell decline in vivo.
    Jurriaans S; de Ronde A; Dekker J; Cornelissen M; Goudsmit J
    J Med Virol; 1995 Jan; 45(1):91-8. PubMed ID: 7714497
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile.
    Tsiang M; Jones GS; Goldsmith J; Mulato A; Hansen D; Kan E; Tsai L; Bam RA; Stepan G; Stray KM; Niedziela-Majka A; Yant SR; Yu H; Kukolj G; Cihlar T; Lazerwith SE; White KL; Jin H
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7086-7097. PubMed ID: 27645238
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Changes to the HIV long terminal repeat and to HIV integrase differentially impact HIV integrase assembly, activity, and the binding of strand transfer inhibitors.
    Dicker IB; Samanta HK; Li Z; Hong Y; Tian Y; Banville J; Remillard RR; Walker MA; Langley DR; Krystal M
    J Biol Chem; 2007 Oct; 282(43):31186-96. PubMed ID: 17715137
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evolution of 2-long terminal repeat (2-LTR) episomal HIV-1 DNA in raltegravir-treated patients and in in vitro infected cells.
    Reigadas S; Andréola ML; Wittkop L; Cosnefroy O; Anies G; Recordon-Pinson P; Thiébaut R; Masquelier B; Fleury H
    J Antimicrob Chemother; 2010 Mar; 65(3):434-7. PubMed ID: 20051476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.